Addressing a broad range of acute and chronic diseases

Our Shielded Living TherapeuticsTM platform combines advanced cell differentiation and engineering techniques with innovations in biocompatible materials, potentially enabling our products to produce a wide range of functions or therapeutics molecules that may be missing or deficient in the body, including proteins, enzymes or other therapeutic molecules.

 

Our pipeline primarily spans a range of endocrine and lysosomal diseases, with the current focus on diabetes. Our product candidates are designed to be off-the-shelf, durable, controllable and redosable, without requiring modification of the patient’s genes or chronic suppression of the patient’s immune system.

 

 

ProgramProg
Cell Product/TypeProd/Type
DiscoveryDisc
Lead OptimizationLead
IND EnablingIND
Phase 1/2Ph 1/2
Lead Program
SIG-002 - Type 1 Diabetes
Human Insulin I
SIG-002 - Type 1 Diabetes
Human Insulin I
Lysosomal Diseases
SIG-205 - CNS MPS-1
BBB - Human IDUA E
SIG-205 - CNS MPS-1
BBB - Human IDUA E
SIG-207 - Fabry
Human GLA E
SIG-207 - Fabry
Human GLA E
SIG-218 - CNS MPS-2
BBB - Human IDS E
SIG-218 - CNS MPS-2
BBB - Human IDS E
SIG-220 - MPS-6
Human ARSB E
SIG-220 - MPS-6
Human ARSB E
Liver Diseases
SIG-XXX - Undisclosed
ApoL-IL10 E
SIG-XXX - Undisclosed
ApoL-IL10 E
SIG-XXX - Undisclosed
Human Hepatocyte I
SIG-XXX - Undisclosed
Human Hepatocyte I
Cell Type

E Epithelial Cell

I iPSC derived

Cell Type

E Epithelial Cell

I iPSC derived

Cell Type

E Epithelial Cell

I iPSC derived

MOA

Constitutive

Sense & Response